Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track QCLS with free AI briefings, catalyst countdowns, and dilution alerts.

QCLS · Q/C TECHNOLOGIES, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11M Cash on Hand
12.9mo Cash Runway
Follow QCLS by email Get an email when QCLS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about QCLS, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

QCLS holds $11M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations, an estimated runway of 12.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when QCLS files for a raise →

👥 Who Owns QCLS

Insiders 7.1% Other 5%+ holders 92.9% Institutions (25 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
PharmaCyte Biotech, Inc. 5%+ holder (13D) 8,475,368 98.33% 2025-11-14
Chelsea Sierra Voss
Director · +262,500 options
Insider 301,455 3.50% 2026-03-30
Joshua Silverman
Executive Chairman, Director · +100,000 options
Insider 210,845 2.45% 2026-07-10
Billy Joe White
Director · +50,000 options
Insider 25,024 0.29% 2025-11-14
Bruce Bernstein
Director · +50,000 options
Insider 25,000 0.29% 2025-11-14
Stephen Friscia
Director · +50,000 options
Insider 25,000 0.29% 2025-11-14
Mitchell Glass
Chief Medical Officer, Director · +175,000 options
Insider 12,500 0.15% 2025-11-14
Gary M Rauch
Vice President of Finance · +75,000 options
Insider 12,500 0.15% 2025-11-14

Share count 8,619,201 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full QCLS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QCLS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.